Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

• Status: Recruiting
• Trial end date: 2023-07-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study designed to assess for relative change in cardiac 18F Florbetapir uptake in patients with AL cardiac amyloidosis after appropriate chemotherapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical College of Wisconsin

Criteria

Inclusion Criteria:

1. Patients aged > 18 years are eligible.

2. Patient must provide informed consent to participate in the study protocol.

3. All patients must have clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or cardiac MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis).

4. Planned plasma cell-directed chemotherapy.

5. A negative pregnancy test will be required for all women of child bearing potential, breast feeding is not permitted.

6. Patients must be able to undergo PET-CT imaging

7. Patients must be able to complete 6-minute walk test

Exclusion Criteria:

1. Severe claustrophobia

2. Pregnancy

3. Allergy to F-18 florbetapir